Context Therapeutics Inc. Announces Positive Phase 1 Interim Results

What Happened

• On June 15, 2026 Context Therapeutics Inc. filed a Form 8-K announcing positive interim efficacy and safety results from its ongoing Phase 1 clinical trial of CTIM-76, an investigational Claudin 6 x CD3 T cell‑engaging bispecific antibody. On the same day the company posted an updated corporate presentation on its website (www.contexttherapeutics.com). The press release and presentation are attached to the 8-K as exhibits.

Key Details

• Date of filing: June 15, 2026.
• Program: CTIM-76 — Claudin 6 x CD3 T cell‑engaging bispecific antibody, currently in a Phase 1 trial.
• Materials posted: updated corporate presentation and a press release reporting the interim efficacy and safety data (filed as Exhibits 99.1–99.3 to the 8-K).
• The 8-K does not include new financial statements or forward financial guidance.

Why It Matters

• Positive Phase 1 interim efficacy and safety data are directly relevant to the company’s clinical progress and could influence investor interest and the perceived value of the CTIM-76 program.
• The updated corporate presentation may provide more detail on the company’s pipeline, trial design, and next steps; investors should review the attached press release and presentation for specific data and timelines.
• This 8-K is a disclosure of clinical progress only — it does not replace full clinical study reports, regulatory filings, or future updates that could affect development outcomes.